TY  - JOUR
AU  - Telli, Tugce
AU  - Lopes, Leonor
AU  - Karpinski, Madeleine
AU  - Pabst, Kim M
AU  - Grünwald, Viktor
AU  - Shi, Kuangyu
AU  - Hadaschik, Boris
AU  - Kesch, Claudia
AU  - Umutlu, Lale
AU  - Herrmann, Ken
AU  - Seifert, Robert
AU  - Fendler, Wolfgang P
TI  - Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC.
JO  - European journal of nuclear medicine and molecular imaging
VL  - 52
SN  - 1619-7070
CY  - Heidelberg [u.a.]
PB  - Springer-Verl.
M1  - DKFZ-2025-00601
SP  - 3199–3210
PY  - 2025
N1  - Volume 52, pages 3199–3210, (2025) 
AB  - To improve [177Lu]Lu-Prostate-specific membrane antigen therapy (LuPSMA) selection, this study investigates the prognostic value of PSMA and 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG)-PET in metastatic castration-resistant prostate cancer (mCRPC) patients considered for LuPSMA therapy.We conducted a retrospective analysis in 152 mCRPC patients referred for LuPSMA therapy who underwent PSMA and [18F]FDG-PET/CT. Of these, 104 patients (68.4
KW  - Biomarkers (Other)
KW  - FDG (Other)
KW  - PSMA (Other)
KW  - Prognostics (Other)
KW  - Prostate cancer (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40113645
DO  - DOI:10.1007/s00259-025-07198-y
UR  - https://inrepo02.dkfz.de/record/300101
ER  -